Trelagliptin: Difference between revisions

Revision as of 16:12, 9 February 2025

Trelagliptin

Trelagliptin is a pharmaceutical drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as DPP-4 inhibitors, which work by increasing the levels of incretin hormones, thereby enhancing the body's ability to lower blood sugar levels.

Mechanism of Action

Trelagliptin functions by inhibiting the enzyme DPP-4, which is responsible for the degradation of incretin hormones such as GLP-1 and GIP. By preventing the breakdown of these hormones, trelagliptin increases their concentration in the bloodstream, leading to improved insulin secretion and decreased glucagon release, ultimately resulting in better glycemic control.

Clinical Use

Trelagliptin is prescribed for the treatment of type 2 diabetes in adults. It is typically used in conjunction with diet and exercise to improve blood sugar control. Unlike some other DPP-4 inhibitors, trelagliptin is administered once weekly, which may improve patient adherence to the treatment regimen.

Side Effects

Common side effects of trelagliptin include nasopharyngitis, headache, and upper respiratory tract infections. As with other DPP-4 inhibitors, there is a potential risk of pancreatitis, and patients should be monitored for symptoms of this condition.

History

Trelagliptin was developed by Takeda Pharmaceutical Company and was first approved for use in Japan in 2015. It is marketed under the brand name Zafatek.

Research and Development

Ongoing research is focused on evaluating the long-term efficacy and safety of trelagliptin, as well as its potential benefits in combination with other antidiabetic agents. Studies are also exploring its impact on cardiovascular outcomes in patients with type 2 diabetes.

Related Pages

References

@@ Line 1: / Line 1: @@
-'''Trelagliptin''' is a medication used for the treatment of [[Type 2 diabetes]]. It is classified as a [[Dipeptidyl peptidase-4 inhibitor]] (DPP-4 inhibitor), a class of drugs that work by blocking the action of DPP-4, an enzyme that destroys the hormone [[Incretin]]. This results in increased levels of Incretin hormones, which help to control blood sugar by increasing insulin production and decreasing glucagon production.
+== Trelagliptin ==
-==Etymology==
+'''Trelagliptin''' is a pharmaceutical drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as [[Dipeptidyl peptidase-4 inhibitors|DPP-4 inhibitors]], which work by increasing the levels of incretin hormones, thereby enhancing the body's ability to lower blood sugar levels.
-The name "Trelagliptin" is derived from the chemical structure of the drug, which includes a triazole ring (tre), a leucine moiety (lag), and a piperidine ring (liptin).
-==Pharmacology==
+=== Mechanism of Action ===
-Trelagliptin works by inhibiting the enzyme [[Dipeptidyl peptidase-4]] (DPP-4). This enzyme is involved in the breakdown of the incretin hormones [[GLP-1]] and [[GIP]]. By inhibiting DPP-4, trelagliptin increases the levels of these hormones, leading to increased insulin production and decreased glucagon production. This helps to control blood sugar levels in people with type 2 diabetes.
+Trelagliptin functions by inhibiting the enzyme [[Dipeptidyl peptidase-4|DPP-4]], which is responsible for the degradation of incretin hormones such as [[glucagon-like peptide-1|GLP-1]] and [[glucose-dependent insulinotropic polypeptide|GIP]]. By preventing the breakdown of these hormones, trelagliptin increases their concentration in the bloodstream, leading to improved insulin secretion and decreased glucagon release, ultimately resulting in better glycemic control.
-==Clinical Use==
+=== Clinical Use ===
-Trelagliptin is used for the treatment of [[Type 2 diabetes]]. It is typically used in combination with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Trelagliptin is not used for the treatment of type 1 diabetes or diabetic ketoacidosis.
+Trelagliptin is prescribed for the treatment of type 2 diabetes in adults. It is typically used in conjunction with diet and exercise to improve blood sugar control. Unlike some other DPP-4 inhibitors, trelagliptin is administered once weekly, which may improve patient adherence to the treatment regimen.
-==Side Effects==
+=== Side Effects ===
-Common side effects of trelagliptin include headache, upper respiratory tract infection, and nasopharyngitis. Serious side effects may include pancreatitis and hypersensitivity reactions.
+Common side effects of trelagliptin include nasopharyngitis, headache, and upper respiratory tract infections. As with other DPP-4 inhibitors, there is a potential risk of pancreatitis, and patients should be monitored for symptoms of this condition.
-==Related Terms==
+=== History ===
-* [[Dipeptidyl peptidase-4 inhibitor]]
+Trelagliptin was developed by [[Takeda Pharmaceutical Company|Takeda Pharmaceutical Company]] and was first approved for use in Japan in 2015. It is marketed under the brand name Zafatek.
+=== Research and Development ===
+Ongoing research is focused on evaluating the long-term efficacy and safety of trelagliptin, as well as its potential benefits in combination with other antidiabetic agents. Studies are also exploring its impact on cardiovascular outcomes in patients with type 2 diabetes.
+== Related Pages ==
+* [[Type 2 diabetes mellitus]]
+* [[Dipeptidyl peptidase-4 inhibitors]]
 * [[Incretin]]
-* [[GLP-1]]
-* [[GIP]]
-* [[Type 2 diabetes]]
-[[Category:Medicine]]
+== References ==
-[[Category:Pharmacology]]
+{{Reflist}}
-[[Category:Diabetes]]
+[[Category:Antidiabetic drugs]]
+[[Category:Dipeptidyl peptidase-4 inhibitors]]
-{{stub}}
+[[File:Trelagliptin.svg|thumb|Chemical structure of Trelagliptin]]
+[[File:Trelagliptin.jpg|thumb|Trelagliptin tablets]]